Lilly’s weight loss drug reduces diabetes risk in overweight patients
Eli Lilly’s weight-loss drug Zepbound dramatically reduces the risk of developing type 2 diabetes in overweight or obese pre-diabetic adults after three years of weekly injections, the drug’s maker said Tuesday.
ENTRADAS POPULARES
North Carolina city sues Duke Energy over climate crisis
diciembre 6, 2024
Earthquake of magnitude 5.7 strikes western Iran
diciembre 6, 2024
Soy traders push to soften ban on buying Amazon produce
diciembre 6, 2024
Tom Tykwer’s ‘The Light’ will open the 2025 Berlin Film Festival
diciembre 6, 2024
TRANSMISIÓN EN VIVO